SomaScan 11K Assay Services
The SomaScan™ 11K Assay Services employ a highly multiplexed, sensitive, quantitative, and reproducible proteomic platform that profiles up to 11,000 human protein measurements in diverse sample types and species – without enrichment or depletion. Ideal for biomarker discovery, it supports basic, translational, pre-clinical, and clinical research across a wide range of diseases.
Gain immediate access to SomaScan Assay
Receive your quote directly from the manufacturer.
Excellent, delicate, sophisticated, prompt
Neuroscience
We have been working with SomaLogic team for our projects, and we received excellent support.
Review Date: 10 Nov 2025 | SomaLogic
The SomaScan 11K Assay Services provide researchers with access to the most comprehensive proteomic platform available – enabling measurement of ~11,000 human proteins with unmatched breadth and reproducibility. This next-generation proteomics technology is designed to accelerate biomarker discovery and deepen biological understanding across the full spectrum of research and drug development.
Key Features & Benefits
- Exceptional proteome coverage: Quantifies ~11,000 human protein measurements from a single sample
- Unmatched reproducibility: ~5% intra- and inter-coefficients of variation (CVs)
- Wide dynamic range: Detects proteins across 10 logs of concentration
- No bridging samples required: Confidently compare cross-sectional and longitudinal data
- Streamlined sample prep: No enrichment or depletion
- CAP/CLIA-accredited lab (U.S.): Scalable for studies of any size, including large clinical trials
- Actionable data outputs: Includes comprehensive, easy-to-interpret reports
Relevant Applications
- Biomarker discovery
- Drug target identification
- Disease mechanism and pathway research
- Large-scale population and cohort studies
- Cross-sectional or longitudinal study designs
- Pre-clinical & clinical research
Ready to advance your research?
Speak with an expert to learn how SomaScan 11K Assay Services can support your next study. Contact us today to get started.
Rethinking neurodegeneration through blood-based biomarkers
Wednesday, October 8, at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT
Proteomics is redefining how we predict, diagnose, and develop treatments for neurodegenerative diseases. Join this roundtable discussion with two leading experts in neurology as they explore the power of blood-based biomarkers, from deep molecular studies to global-scale datasets with the SomaScan™ Assay:
- Tony Wyss-Coray, PhD (Stanford University School of Medicine) will discuss how combining protein measurements in blood and cerebrospinal fluid with genetic data has revealed valuable insights into brain aging.
- Jacob Vogel, PhD (Lund University) will present discoveries from the Global Neurodegeneration Proteomics Consortium (GNPC), revealing protein signatures that predict dementia, identify multiple pathologies, and track changes in protein networks over time.
This roundtable discussion will be moderated by Steve Williams, MD, PhD (Chief Medical Officer, Standard BioTools).
Secure your spot today to hear what the next decade of neurological research could look like.
Key learning objectives:
- Blood vs. brain biomarkers: Can plasma replace or complement CSF?
- Early detection: How can protein patterns predict dementia before symptoms appear?
- Data scale: Is bigger always better, or is deeper profiling the key?
Who should attend?
Translational and clinical researchers studying neurology and aging across all research sectors (e.g., academia, biotech, government, biopharma).
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
